Finance

Cognitive disorders-focused company reports loss of $0.11 per share

Published in Drug Week, December 16th, 2005

Axonyx, Inc. (AXYX), announced results for the third quarter-ended September 30, 2005, reporting a net loss of $5,687,000 or $0.11 per share for the third quarter of 2005 compared to a net loss of $6,693,000 or $0.13 per share for the third quarter of 2004.

There was no revenue for the quarter ended September 30, 2005 as compared to $954,000 in the third quarter of 2004. The change in revenue reflects the fact that Oxis operations are no longer consolidated with our results effective March 1, 2005, and all revenue for the prior periods was derived from Oxis.

Research and development costs were $5,135,000 and $6,054,000 for the 3 months ended...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2005-12-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry